Analyst Price Target is GBX 0
This price target is based on 0 analysts offering 12 month price targets for Consort Medical plc (CSRT.L) in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a NaN upside from the last price of GBX 0.
Current Consensus is
The current consensus among 0 polled investment analysts is to n/a stock in Consort Medical plc (CSRT.L). This rating has held steady since January 2021, when it changed from a Hold consensus rating.
Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices. It operates through two divisions, Bespak and Aesica. The company provides various life improving treatments to patients across worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products. It also develops, formulates, and manufactures active pharmaceutical ingredients and finished dose drugs. Consort Medical plc was incorporated in 1946 and is headquartered in Hemel Hempstead, the United Kingdom.